A Phase II safety, tolerability and pharmacokinetics study of omadacycline in female patients with uncomplicated Urinary tract infections.
Phase of Trial: Phase II
Latest Information Update: 09 May 2018
At a glance
- Drugs Omadacycline (Primary)
- Indications Urinary tract infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Paratek Pharmaceuticals
- 09 May 2018 According to a Paratek Pharmaceuticals media release, phase II UTI data expected in the second half of 2019.
- 01 Mar 2018 Status changed from planning to recruiting, according to a Paratek media release.
- 05 Jan 2018 New trial record